Stock analysts at UBS Group initiated coverage on shares of Natera (NASDAQ:NTRA – Get Free Report) in a research report issued on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $435.00 price target on the medical research company’s stock. UBS Group’s target price would suggest a potential upside of 33.36% from the stock’s current price.
NTRA has been the subject of several other reports. Citigroup boosted their target price on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Rothschild & Co Redburn initiated coverage on shares of Natera in a research note on Tuesday. They issued a “buy” rating and a $385.00 price objective on the stock. Guggenheim boosted their price objective on shares of Natera from $290.00 to $360.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Barclays reaffirmed an “overweight” rating and issued a $340.00 target price on shares of Natera in a report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $330.83.
Check Out Our Latest Report on Natera
Natera Stock Up 0.6%
Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. Natera’s revenue for the quarter was up 37.7% compared to the same quarter last year. As a group, research analysts anticipate that Natera will post -1.02 EPS for the current year.
Insider Activity at Natera
In other news, CEO Steven Chapman sold 1,698 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $320.99, for a total value of $545,041.02. Following the completion of the transaction, the chief executive officer directly owned 98,199 shares in the company, valued at approximately $31,520,897.01. This represents a 1.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 15,160 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40. Following the sale, the insider directly owned 110,859 shares in the company, valued at approximately $36,238,698.51. This trade represents a 12.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 71,206 shares of company stock worth $19,944,069. Corporate insiders own 5.05% of the company’s stock.
Institutional Trading of Natera
A number of hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System grew its holdings in shares of Natera by 28,373.5% during the second quarter. California State Teachers Retirement System now owns 56,324,789 shares of the medical research company’s stock worth $15,289,364,000 after purchasing an additional 56,126,974 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. BlackRock Inc. acquired a new position in Natera in the 2nd quarter valued at approximately $2,962,770,000. Wellington Management Group LLP increased its position in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. Finally, State Street Corp raised its stake in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after acquiring an additional 72,087 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
About Natera
Natera, Inc is a diagnostic company that develops and commercializes molecular testing services based on cell-free DNA and other genetic technologies. The company’s tests are designed to help clinicians assess genetic and reproductive health, monitor organ transplants, and detect and track cancer.
Its principal products include Panorama, a noninvasive prenatal screening test; Horizon, a carrier screening test; Signatera, a personalized circulating tumor DNA test used in cancer monitoring; and Prospera, a molecular test intended to help assess the risk of organ transplant rejection.
Featured Stories
- Five stocks we like better than Natera
- Cathie Wood Trimmed Palantir, But the Bigger Story Is Still Valuation
- Intel’s ASML Milestone Gives Investors a New Reason to Revisit the Stock
- Defense, Solar, and Refining Stocks Split as the Iran Conflict Raises Energy Risk
- 3 Stocks to Buy and Hold for Higher Interest Rates
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
